Psyence Biomed Announces Phase IIb Clinical Trial Listing On The Australian New Zealand Clinical Trials Registry
Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that details of its upcoming Phase IIb clinical trial of nature-derived psilocybin in patients diagnosed with Adjustment Disorder